Mersana Therapeutics, an early-stage biotech developing antibody drug conjugate therapies for cancers, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Mersana Therapeutics plans to list on the Nasdaq under the symbol MRSN. J.P. Morgan, Cowen & Company and Leerink Partners acted as lead managers on the deal.
The article Early-stage biotech Mersana Therapeutics prices IPO at $15, within the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.